Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah I think out of 400+ trials there are like 50 successful gbm candidates!? ;-p
Shorts are a bunch of rubes
Hydrobot....LOL love it. Now with extra lying power!
"endpoints met are endpoints met"
Heck yea, $NWBO is really holding solidly, the DD is pure there, I mean endpoints met are endpoints met... there's no twisting those facts lol. Everyone who's ever been in biotech plays knows what happens when it's a failure lol this is clearly not that case. Should be fun soon!
— BJ57 (@BJ5715) August 18, 2022
To add colour to this even though the numbers aren't huge yet there are some (11) tutes involved.
These are a truely unique confluence of positive factors creating significant tailwinds for our company. I have said many times that we are largely derisked though now of course with the caveat of minor dilution. Yet we still have an immensely valuable oncology platform and a pending combination patent. Even better times are soon ahead in my opinion which should be worth celebrating.
Yes and engagement with medical all across Canada. Plus anything else that is needed. It is a band of genius individuals doing everything in their power to get this done. Many parallel tracks are being pursued concurrently. This is why I believe complaints about management miss the mark, but you are free to think what you want.
Cheers
Thx Hank
No problem. It does give some added color to when things really start to pop off around here. End of September is my birthday so hopefully they get the timing right :)
Interesting. Link?
I wonder what Kristyn Power is doing all day.. wasn't she suppose to prepare to get bigger fish in?
Nice! Username checks out. I love your bright and positive response. Have a great day
Thx BB!
Mine was also in the same time frame. But only 0.6% of that ; o )
I believe it was an earlier discussion on it and that it was the SAP. The basic idea is no news is good news from the FDA
The flashworks acquisition made me jump in with both feet. Stellar results plus the ability to deliver. Mindblowing potential here :)
I believe this is in reference to the combo trials. I know they are more recent she does mention a combo trial that started enrollment in 2020 and has 20 patients so far. But my guess is 2018/2019 without doing any research. Cheers
Here is the you tube link to Linda’s presentation:
Thanks for the transcription! You can see nwbo overwhelming the opposition with many moving parts.
My local crashologist will be proud!
Thanks for this post CO! I've saved it so that I can share it if ever I'm again frustrated by pathological fudsters
My cost avg is down to 74 cents. Bright skies ahead :)
My response is just based on a conversion of those shares to common shares in relation to the outstanding shares. Just spitballin here but still 250 million shares is a lot of shares... I agree with CO that this 8k is significant
Whoever scoops those shares would get approximately 20% voting interest in the company
Thx CO both ideas are excellent
Screenshot of relevant page. Cheers
LL helped edit. SOC and #dcvax mentioned pic.twitter.com/rTjrS6zHW4
— Flexroy (@MSICFFord) July 21, 2022
Merck said the study results show that locally advanced HNSCC remains very challenging to treat, adding that it is committed to investigating Keytruda-based regimens in earlier stages of the disease.
Interesting
Sense making 101
Although I feel bad that it was at Femike's expense ; o )
I like the cut of your jib
This seems to be reasonable. Since she probably had to make herself available for queries and edits. What a crazy long process though!
As someone said to me. 'Imagine in the middle of covid someone calling you at your hospital to ask you to look up some patient data from 5 years ago to be verified. It would definitely fall to the bottom of my priority list..' This is what makes it so difficult.
This must have been causing Nwbo staff crazy headaches in trying to get this journal published. I think now given that she is free to travel is a good sign. :)
Here is a slide summary of Sashi's portion of the Three P's presentation.
That PR is a highly significant event despite what Fudsters will have you believe about management AND in spite of what MMs are trying to convince you about the price.
They have the demand (Procurement)
They have the manufacturing (Process)
They have the supply (Product)
Flashworks is an intrinsic part of their automation process and their scale up to 1000/mo. The PR states that they are near the end of this process and have applied for commercial licensing. Expect approval by the end of year.
Shashi's presentation makes it clear. Previous PRs refer to comparability studies to be run in the summer in relation to Flashworks. Any downplay of the significance of the PR is facile at best and intentional at worst.
I have included shots of the slides below and will now go for a run. Cheers to the long suffering longs!
I strongly disagree with both of you I think this is more likely that a BLA has been submitted given the amount of staff they have and the amount of ramp up that we've seen.
I think it's more than just an IND that has been submitted. Although it is not proof positive it's not to be taken lightly I think this is a really big deal.
Highlights
4:50 Dr. P talks about toxicity and informed consent, Personal angle, his wife had ovarian cancer
A perfect segue to....
6:15 - 9:15 Project Orbis - "How can we leverage that to help these other countries. We work together on these applications. Promotes rapid development and rapid approval of drugs. Worldwide... Impacts SOC faster."
11:00 Destroys the "make the dose higher" argument mentioned earlier on this board (really, who said that??)
14:05 - The whole CRO industry is bureaucratic. Argues for simplicity
thanks again for this post
In part 2 of this @ASCO podcast, hosts Dr. David Johnson and Dr. Patrick Loehrer continue their conversation with Dr. Richard Pazdur, including reflection on drug toxicities, approval processes, and complexity of clinical trials.https://t.co/IHtX2wEmoJ
— FDA Oncology (@FDAOncology) June 28, 2022
Nice post Flip
This is true.
If not now, When? If not you, then Who?
That is literally what went through my head this morning when I realized nothing had been uploaded to YouTube for greater access.
GLTU
Just doing my part. Sometimes it feels like there is only ten of us making things happen :)
It's on YouTube now. A transcription function is a part of the interface. Cheers!
Dr Stupp
hoff
doc
newman
flip
thx and cheers
I think it is @metacollective or something like that. It's in the feed
Buoyed by the positive chatter in the UK. The truth is out.
But lets not forget why we are here. My neighbour passed from GBM just this morning. They found two inoperable dark spots on her scans just two weeks ago after she had a seizure.
She had been grumpy of late complaining about her vision. I thought it was allergies. My kids knew her as the perogy lady because she was always making us perogies, more than we could eat. Sad.
I'm not sharing for any responses, I'm sharing so we remember why we're here. Been a strange couple of weeks meeting execs from nwbo then hearing about my neighbour all on the same day. Crazy world.